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  ABSTRACT 
Renal failure is a common disease in Sudan, the estimated 
incidence is 70 -140/ million inhabitation/year. Malaria, 
schistosomiasis and tuberculosis not very common in Sudan 
associated with glomerulonephritis.  
Renal transplant operations offered the possibility of 
restoring normal kidney functions and thereby correct the many 
metabolic abnormality of uraemia.  
Renal replacement therapy in Sudan started in 1968 and 
the first renal transplant operation had done in 1974.  
In Sudan the majority of renal transplant operations were 
done between 1986 - 1991. In the late 1990s renal transplant 
program reactivated in Ahmed Gasim and Ibn Sina Hospitals, 
however, the number of renal transplants done intermittently in 
these centers is small compared with the number of potential 
recipients candidates. 
This is a retrospective study conducted in the period from 
January to June 2004.  
The main objectives of the study is to determine the 
percentage of normal renal graft function five years after 
 
  
  
 
  transplantation and to correlate the graft survival with duration of 
dialysis before transplantation and the gender of the donor. Of 
renal allograft recipients attending Dr. Salma Mohamed Suleiman 
Centre for Dialysis and Kidney Transplantation, hundred cases 
were selected randomly. The selection criterion was renal allograft 
recipients of five years duration or more. 
 The data were entered and analysed using Statistical 
Package for Social Science Software (SPSS) computer. The analysis 
of the data showed that:  
• Most of graft recipients (63%) were males, whereas only 21% of 
graft donors were females. 
• About two third of allograft recipients had normal graft 
function.  
• Most of allograft recipients (61%) received both haemo and 
peritoneal dialysis.  
• No difference in allograft function between recipients of male 
and female kidney.  
• Direct proportion between duration of dialysis before 
transplantation and allograft dysfunction.    
  
 
  
  
 
  ﻤﻠﺨﺹ ﺍﻷﻁــﺭﻭﺤـﺔ  
 - 07ﻤﺭﺽ ﺍﻟﻔﺸل ﺍﻟﻜﻠﻭﻯ ﺍﻟﻤﺯﻤﻥ ﺸﺎﺌﻊ ﺒﺎﻟﺴﻭﺩﺍﻥ ﻭﻴﻘﺩﺭ ﻋﺩﺩ ﺍﻹﺼـﺎﺒﺎﺕ ﺒــ 
ﻟﺒﻠﻬﺎﺭﺴﻴﺎ ﻭﺍﻟﺩﺭﻥ ﻤﻥ ﺍﻷﻤﺭﺍﺽ ﺍﻟﺘﻰ ﺘـﺴﺒﺏ ﺍﻟﻤﻼﺭﻴﺎ ﻭﺍ .  ﻟﻜل ﻤﻠﻴﻭﻥ ﻤﻥ ﺍﻟﺴﻜﺎﻥ ﻓﻰ ﺍﻟﻌﺎﻡ 041
  . ﺍﻟﺘﻬﺎﺏ ﺍﻟﻜﺒﻴﺒﺎﺕ ﺍﻟﻜﻠﻭﻴﺔ ﺍﻟﺤﺎﺩ ﺒﺎﻟﺴﻭﺩﺍﻥ
ﺯﺭﺍﻋﺔ ﺍﻟﻜﻠﻰ ﺘﺅﺩﻯ ﻻﺴﺘﻌﺎﺩﺓ ﺍﻟﻭﻅﻴﻔﺔ ﺍﻟﻁﺒﻴﻌﻴﺔ ﻟﻠﻜﻠﻰ ﻭﺘﺼﺤﻴﺢ ﻤﻌﻅﻡ ﺍﻻﻀﻁﺭﺍﺒﺎﺕ 
  . ﺍﻹﺴﺘﻘﻼﺒﻴﺔ ﺍﻟﻤﺼﺎﺤﺒﺔ ﻻﺭﺘﻔﺎﻉ ﻤﺴﺘﻭﻯ ﺍﻟﺒﻭﻟﻴﻨﺎ ﻓﻰ ﺍﻟﺩﻡ
ﻡ ﻭﺘﻤـﺕ ﺃﻭل 8691ﺎﻡ ﺒﺩﺃﺕ ﻋﻤﻠﻴﺔ ﺍﻻﺴﺘﺴﻘﺎﺀ ﺍﻟﺒﺭﻭﺘﻭﻨﻲ ﻭﺍﻟﺩﻤﻭﻯ ﻓﻰ ﺍﻟﺴﻭﺩﺍﻥ ﻋ 
ﻤﻌﻅﻡ ﻋﻤﻠﻴﺎﺕ ﺯﺭﺍﻋﺔ ﺍﻟﻜﻠﻰ ﺍﻟﺘﻰ ﺃﺠﺭﻴﺕ ﻓﻰ ﺍﻟﺴﻭﺩﺍﻥ ﻜﺎﻨـﺕ . ﻡ4791ﻋﻤﻠﻴﺔ ﺯﺭﺍﻋﺔ ﻜﻠﻰ ﻋﺎﻡ 
ﻡ ﻗﺒل ﺘﻨﺸﻴﻁ ﺒﺭﻨﺎﻤﺞ ﺯﺭﺍﻋﺔ ﺍﻟﻜﻠﻰ ﻓﻰ ﻤﺭﻜﺯﻯ ﺇﺒﻥ ﺴـﻴﻨﺎ ﻭﺃﺤﻤـﺩ 1991 - 6891ﻤﺎ ﺒﻴﻥ ﻋﺎﻡ 
ﻗﺎﺴﻡ ﻓﻰ ﺃﻭﺍﺨﺭ ﺍﻟﺘﺴﻌﻴﻨﺎﺕ، ﺇﻻ ﺃﻥ ﻋﻤﻠﻴﺎﺕ ﺍﻟﺯﺭﺍﻋﺔ ﺍﻟﺘﻰ ﺘﺠﺭﻯ ﻓﻰ ﻫـﺫﻩ ﺍﻟﻤﺭﺍﻜـﺯ ﺒـﺼﻭﺭﺓ 
  . ﺔ ﻗﻠﻴﻠﺔ ﻤﻘﺎﺭﻨﺔ ﺒﻌﺩﺩ ﺍﻟﻤﺭﻀﻰ ﺍﻟﻤﺭﺸﺤﻴﻥ ﻟﻠﺯﺭﺍﻋﺔﻤﺘﻘﻁﻌ
ﺍﻷﻫـﺩﺍﻑ . ﻡ4002 ﻴﻭﻨﻴـﻭ -ﻫﺫﻩ ﺩﺭﺍﺴﺔ ﻭﺼﻔﻴﺔ ﺃﺠﺭﻴﺕ ﻓﻰ ﺍﻟﻔﺘﺭﺓ ﻤﺎ ﺒﻴﻥ ﻴﻨﺎﻴﺭ 
ﺍﻷﺴﺎﺴﻴﺔ ﻟﻠﺩﺭﺍﺴﺔ ﻫﻰ ﻤﻌﺭﻓﺔ ﻨﺴﺒﺔ ﺍﻟﺫﻴﻥ ﻴﺘﻤﺘﻌﻭﻥ ﺒﻭﻅﻴﻔﺔ ﻁﺒﻴﻌﻴﺔ ﻟﻠﻜﻠﻰ ﺍﻟﻤﺯﺭﻭﻋﺔ ﺒﻌﺩ ﺨﻤـﺱ 
ﺎﺀ ﻗﺒل ﺍﻟـﺯﺭﻉ ﻭﺠـﻨﺱ ﺴﻨﻭﺍﺕ ﻤﻥ ﺍﻟﺯﺭﺍﻋﺔ ﻭﻤﻘﺎﺭﻨﺔ ﻭﻅﻴﻔﺔ ﺍﻟﻜﻠﻰ ﺍﻟﻤﺯﺭﻭﻋﺔ ﻤﻊ ﻤﺩﺓ ﺍﻹﺴﺘﺴﻘ 
  . ﺍﻟﻤﺘﺒﺭﻉ
ﺴـﻠﻤﻲ ﻤﺤﻤـﺩ ﺴـﻠﻴﻤﺎﻥ / ﻤﻥ ﺒﻴﻥ ﺯﺍﺭﻋﻰ ﺍﻟﻜﻠﻰ ﺍﻟﺫﻴﻥ ﻴﺘﺎﺒﻌﻭﻥ ﻓﻰ ﻤﺭﻜﺯ ﺩﻜﺘﻭﺭﺓ 
ﺍﻟﻤﺨﺘﺎﺭﻭﻥ ﻫﻡ ﺍﻟﻤﺭﻀﻰ ﺯﺍﺭﻋـﻰ .  ﻤﺭﻴﺽ ﺒﻁﺭﻴﻘﺔ ﻋﺸﻭﺍﺌﻴﺔ001ﻟﻐﺴﻴل ﻭﺯﺭﺍﻋﺔ ﺍﻟﻜﻠﻰ ﺃﺨﺘﻴﺭ 
  .  ﺴﻨﻭﺍﺕ ﺃﻭ ﺃﻜﺜﺭ5ﺍﻟﻜﻠﻰ ﻟـ 
ﻴـل ﺃﺩﺨﻠﺕ ﺍﻟﺒﻴﺎﻨﺎﺕ ﺠﻬﺎﺯ ﺍﻟﺤﺎﺴﻭﺏ ﻭﺤﻠﻠـﺕ ﺒﺎﺴـﺘﻌﻤﺎل ﻁﺭﻴﻘـﺔ ﺤﺯﻤـﺔ ﺍﻟﺘﺤﻠ 
  . ﺍﻹﺤﺼﺎﺌﻲ
  
 
  
  
 
  : ﻤﻥ ﺘﺤﻠﻴل ﺍﻟﺒﻴﺎﻨﺎﺕ ﺍﺘﻀﺢ ﺃﻥ  
  . ﻓﻘﻁ ﻤﻥ ﺍﻟﻤﺘﺒﺭﻋﻴﻥ ﻨﺴﺎﺀ% 12ﺭﺠﺎل ﺒﻴﻨﻤﺎ %( 36)ﻤﻌﻅﻡ ﺍﻟﺯﺍﺭﻋﻴﻥ  •
ﺜﻠﺜﻰ ﺍﻟﺯﺍﺭﻋﻭﻥ ﻴﺘﻤﺘﻌﻭﻥ ﺒﻭﻅﻴﻔﺔ ﻁﺒﻴﻌﻴﺔ ﻟﻠﻜﻠﻰ ﺍﻟﻤﺯﺭﻭﻋﺔ ﺒﻌﺩ ﺨﻤﺱ ﺴﻨﻭﺍﺕ ﺃﻭ ﺃﻜﺜﺭ ﻤـﻥ  •
  . ﺍﻟﺯﺭﻉ
  . ﻟﺯﺭﻉﺘﻠﻘﻭﺍ ﺍﻟﻨﻭﻋﻴﻥ ﻤﻥ ﺍﻻﺴﺘﺴﻘﺎﺀ ﺍﻟﺒﺭﻭﺘﻭﻨﻲ ﻭﺍﻟﺩﻤﻭﻯ ﻗﺒل ﺍ%( 16)ﻤﻌﻅﻡ ﺍﻟﺯﺍﺭﻋﻴﻥ  •
  . ﻻ ﻴﻭﺠﺩ ﺘﺄﺜﻴﺭ ﻟﺠﻨﺱ ﺍﻟﻤﺘﺒﺭﻉ ﻋﻠﻰ ﻭﻅﻴﻔﺔ ﺍﻟﻜﻠﻰ ﺍﻟﻤﺯﺭﻭﻋﺔ •
  . ﺘﺘﻨﺎﺴﺏ ﻤﺩﺓ ﺍﻻﺴﺘﺴﻘﺎﺀ ﻗﺒل ﺍﻟﺯﺭﻉ ﺘﻨﺎﺴﺒﺎﹰ ﻁﺭﺩﻴﺎﹰ ﻤﻊ ﺘﺩﻫﻭﺭ ﻭﻅﻴﻔﺔ ﺍﻟﻜﻠﻰ ﺍﻟﻤﺯﺭﻭﻋﺔ •
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INTRODUCTION 
 
Renal failure is a common disease in Sudan, the estimated 
Incidence for new cases is 70-140/million inhabitation /year, the 
majority are young patients below 40 years of age and most of 
them die before reaching medical attention.(1)  
In 1990 a study was done in Sudan about chronic 
glumerulonephritis (G.N) in adult Sudanese patients with chronic 
renal failure. It showed that patient with chronic G.N are within 
the age group 21-30 years, unlike those with other renal disease 
who are older [more than 40 years].(2) 
In Sudan there are many endemic diseases known to affect 
the kidneys: malaria, schistosomiasis, leprosy, tuberculosis are not 
very commonly associated with G.N and nephrotic syndrome. 
Successful renal transplantation offers the potential for 
almost complete rehabilitation in end stage renal disease 
[E.S.R.D.]. It allows freedom from dietary and fluid restriction, 
anaemia and infertility corrected and the need for 
parathyroidectomy is reduced.(3)  
  2
In recent years between 12000 and 14000 kidney 
transplants have been performed annually in the United States.(4)  
Marked improvement in graft survival has made renal 
transplantation the treatment of choice for E.S.R.D.  
For the cohort of United States patients transplanted in 
1994 one-year allograft survival was 92.4% for recipients of living 
related donors allograft.(4)     
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LITERATURE REVIEW 
  
History of renal replacement therapy in Sudan: 
Dialysis:  
Renal replacement therapy [R.R.T] in Sudan started in 
1968 with peritoneal dialysis [PD] in a small centre in the old 
building of K.T.H. In 1970 a renal unit was opened in Khartoum 
Teaching Hospital (KTH) with 2 beds for P.D, two haemodialysis 
machines were added in 1973.  
Soba University Hospital started working in 1975 with two 
peritoneal dialysis beds and two haemodialysis machines. Ibn Sina 
Hospital started in 1983 with 2 beds for P.D and two 
haemodialysis machines as well. In the same year Khartoum 
Dialysis and Kidney Transplant Centre [K.D.K.T.C] started with 
haemodialysis machines.      
At present there are 17 working haemodialysis machines 
in Dr. Salma Mohamed Suleiman Kidney Dialysis and 
Transplantation Centre dializing 153 patients every week [3 shifts, 
6 days per week]. There are 7 haemodialysis machines in Soba 
University Hospital Dialyzing 21 patients a week. Also there are a 
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9 haemodialysis machines in Ibn Sina Hospital. In K.T.H now there 
are 15 working haemodialysis machines dialyzing 90 patients a 
week (two shifts 6 day per week). New machines in Military 
Hospital, Khartoum North Teaching Hospital, Omdurman 
Teaching Hospital and Rabat University Hospital (ten working HD 
machines) are been added to present setting.  
A centres of haemodialysis opened in Port-Sudan, Wad 
Medani and Atbara. There are 10 peritoneal dialysis (P.D) beds in  
K.T.H and 6 beds in Soba Hospital.  
Transplantation:  
The first renal transplant in Sudan was done in 1974 in old 
building of K.T.H, the majority of renal transplant operations were 
done between 1986-1991. All transplant were from living related 
donors, operations were done either in Ibn Sina or Soba University 
Hospital by the same team.  
In the late 1990s renal transplantation programe 
reactivated in Ahmed Gasim and Ibn Sina centres with 
governmental fund for 50 percent of the cost of each transplant, 
but transplantation done irregularly because it faced by many 
problems. Most of the patients can not afford paying 50 percent of 
  5
the cost. Also the numbers of renal transplants done intermittently 
in these centres is small compared with the number of waiting 
patients. 
At present there are about 313 renal transplant recipients 
attending Dr. Salma Mohamed Suleiman Centre for Dialysis and 
Kidney Transplantation for follow up. The majority has their 
operations done in Saudi Arabia, the rest were done in Egypt, 
Kuwait, Jordan, India, European countries and Sudan. All 
transplants were from living donors, transplantation from 
cadaveric donors is facing a great opposition from Islamic scholars 
in Sudan.(1)    
Importance of renal transplantation:  
Renal transplantation offers the possibility of restoring 
normal kidney function and thereby corrects the many metabolic 
abnormalities of uraemia.[5] 
More recent data suggests that the long-term allograft 
survival is improving over time. Among nearly 100,000 transplant 
performed bet 1988 and 1996 in the United States, the half-life for 
cadaveric and living-related allograft have improved to 13.8 and 
21.6 years respectively.(5)  
  6
Recipient evaluation:  
Screening of potential recipient candidates is important to 
exclude uncontrolled psychosis, ongoing substance abuse, medical 
non-compliance, active infection with HIV, active peptic ulcer 
disease, severe secondary hyperparathyroidism, and 
cardiovascular diseases. Also patients need to be evaluated for 
hepatitis-B antigenaemia and hepatitis C viraemia as renal 
transplantation is relatively contra-indicated in these patients.[6]   
Donor evaluation:  
In general evaluation of potential living donors is geared 
to determine whether there is medical conditions that will put the 
donor at increasing risk for complications of general anaesthesia 
and surgery, and whether the removing of one kidney will 
increase the donor risk for developing renal insufficiency.(4)  
The followings are relatively contra-indications to kidney 
donation:  
- Age: > 65 years.  
- Advanced medical illness.  
- Severe hypertension.  
- Diabetes mellitus.  
  7
- Active infection.  
- Pre-existing renal disease.(6)   
The following tests are performed as part of the living 
donor evaluation:  
- Complete blood count.  
- Urinalysis.       
- Urine culture.  
- Echocardiography.  
- Serologic studies for past exposure to 
infections (cytomegalovirus, hepatitis B and C, Epstein-
Barr virus, syphilis, H.I.V)  
- Renal imaging studies (ultrasound, 
intravenous urogram, and angiographies).(4)  
Recipient-Donor Matching:   
Mismatching Rhesus (Rh) types are not important in organ 
transplantation, however, the donor and recipient generally must 
be ABO compatible.[4] 
The major histocompatibility complex [H.M.C] antigens 
measured routinely in most HLA laboratories include the class I 
antigens [A, B and C] and class II [D].  
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Practically the antigens used for matching prior to kidney 
transplant are A, B and DR. Of individual antigen, matching for 
DR-antigen appears to result in the most favorable long term 
outcome for the allograft.[4]  
An increased degree of HLA antigen mismatching is 
associated with a greater risk of chronic graft loss presumably due 
to specific immunologic injury.(7) More specific HLA matching: 
based on evolving knowledge of the structure of HLA molecules, 
the way in which HLA types are matched is now being 
reconsidered. On each HLA molecule, there are four to five regions 
having amino acid differences, which are called epitopes. 
Together, they define a given antigen, but individually they vary 
in their ability to immunize.(8)  
Anatomy of the transplant:  
It should be remembered that under some circumstances, a 
renal transplant is inserted into the contralateral iliac fossa of the 
recipient and is inverted as a consequence. The renal pelvis then 
lies anterior to renal artery and vein. The arterial anastomosis is 
usually end to end between donor renal artery and recipient 
internal iliac artery, and the venous anastomosis end to side 
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between the renal vein and common iliac vein. The transplant is 
denervated, making intervention procedures relatively painless. 
The uncomplicated transplant is assessed by a baseline 
ultrasound.[9]  
Risk factors for graft failure:  
i. History of maintenance dialysis:   
Allograft survivals vary with the use of maintenance 
dialysis or the type of dialysis prior to surgery.  
In retrospective study of over 8000 patients, preemptive 
transplantation of living donor kidney was associated with a 52 
and 82 percent lower risk of allograft failure at one and two years 
after transplantation respectively, compared to that for patient 
undergoing maintenance dialysis prior to transplantation.[10]  
In study of over 20.000 transplant recipients the prior use 
peritoneal dialysis was associated with 23 percent high risk of 
allograft failure during the 1st 3 months post transplant versus that 
observed with haemodialysis.[11]  
ii. Transfusion effect:  
In the early 1970s, it was observed that patients receiving 
pre-transplant transfusion have a 20 percent improvement in graft 
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survival compared to those who had not been transfused.[12] 
However, registry data suggest that this beneficial effect 
diminished to a 10 percent improvement by the 1980s and has 
almost disappeared in 1990s. Although this decremental benefit is 
commonly thought to be related to cyclosporine, it actually 
predate the wide spread use of this drug.  
iii. Disproportionately fewer nephrons:  
A greater demand upon transplanted kidney may be 
observed in recipients of donor kidneys from those with fewer 
nephrons and for those from relatively smaller sized individuals, 
such as donor female kidney to male recipient. As with large sized 
recipient, the different in nephron numbers may be a reason for a 
lower long-term survival rates observed among male recipients of 
female kidneys.  
Determined influence of female donor gender on the 
outcome of cadaver kidney graft have been observed in both 
primary and re-transplant situation. Nephron overload, induced 
by smaller size of female donor kidneys, is hypothesized to be 
responsible for the poor outcome of female organs in male 
recipients. However, the possibility of increased risks of acute 
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rejection or technical failure may also contribute to the poor 
outcome of female to male transplant.[13]  
The half-life of male cadaver grafts transplanted into 
female recipients is 8.4 years as compared with 6.9 years for male 
recipients of female kidneys.[14]  
iv. Old and very young donor kidneys:  
Old and very young donor kidneys have relatively 
decreased number of functioning nephrons and survive less well 
when transplanted. In addition to fewer nephrons, other factors 
inherent to an older kidney may also influence over-all allograft 
survival.[15]  
v. Drug noncompliance:  
Non compliance is one of the more important risk factor 
for renal graft loss.(16)  
In a single centre series for example noncompliance 
accounted for at least 11 and 13 percent of living donor and 
cadaveric allograft loss respectively.[17]  
vi. Hyperlipidaemia:  
hyperlipidaemia is an established risk factor for 
arteriosclerosis and coronary artery disease in all patients 
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including cardiac and renal transplant recipients, it may result in 
increased graft loss in recent transplantation, one study found that 
hyper-triglyceridaemia was strong predictor of subsequent 
allograft loss.[18]  
vii. Ischaemia and/or re-perfusion injury:  
Ischaemia and/or re-perfusion injury is thought to be 
critical risk factor for both early delayed graft function and late 
allograft dysfunction.  
The dominant cause of delayed graft function is post-
ischaemia acute tubular necrosis (ATN).[19]  
The incidence of this complication increased when the cold 
ischaemia time exceeds 24 hours.[20]  
viii. Episodes of acute rejection:  
Patients with history of acute rejection episodes are more 
likely to develop chronic dysfunction or rejection than those  
without such episodes. In a Minnesota study, for example, 20 
percent of living donor recipients and 36 percent of cadaver donor 
recipients who sustained an acute rejection episodes within the 
first 60 days post-transplant subsequently developed chronic 
rejection.[21] In comparison patients with no history of rejection has 
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less than one percent chance of eventually developing chronic 
disease.  
ix. Delayed graft function:  
Acute tuber necrosis [A.T.N] caused by ischaemia is the 
most common cause of delayed graft function.   
Generally, kidneys that have a long time interval from 
harvesting to engraftment have high incidence of A.T.N in 
addition the transplanted kidney subjected to the same causes of 
A.T.N that lead to renal dysfunction in the native kidneys.(6)  
Immunosuppressive drugs:  
In 1950s when clinical renal transplantation began, 
sublethal total body irradiation was employed. We have now 
reached the point where sophisticated pharmacologic 
immunosuppression is available, but it is still has the hazard of 
promoting infections and malignancies. In general more clinically 
useful drugs are more sensitive to primary than to memory 
immune responses.(22)   
Maintenance immunosuppression is necessary to prevent 
immunologic rejection of the allografts, except in the situation of 
an identical twin transplant.(6)  
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Azathioprine:  
The immunosuppressive effect of azathioprine [Imuran] is 
dependent on its conversion in liver to 6-mercaptopurine, which is 
active drug. It inhibits Purine nucleotide metabolism thereby 
interfering with DNA replication. The initial dose is usually           
2-4 mg/kg/day. Oral and intravenous doses are equivalent.  
The complications associated with the use of azathioprine 
include leukopenia, megaloblastic erythropoises, anaemia and 
thrombocytopenia, hepatocellular injury, cholestatic jaundice, 
pancreatitis, arthritis, interstitial nephritis, pneumonitis, 
malignancies and allopecia.(6)  
Corticosteroids:  
Are used as adjunctive therapy in combination with 
azathioprine or cyclosporine A [CsA] for maintenance immuno-
suppression. They block the elaboration of critical cytokines 
including interleukin-1, interleukin-6 and tumour necrosis factor 
by activated macrophages, which is an important step in T-cell 
activation. Prednisolone is usually started at a dose of                     
0.5 - 2 mg/kg/day and is then gradually reduced to approximately 
10mg/day by 3-6 months after transplantation. Complications of 
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corticosteroid therapy includes impaired glucose metabolism, 
hyperlipidaemia, aseptic necrosis of the bone, cataracts, myopathy, 
easy bruisability, acne, hypertension and mood liability. 
Cyclosporine A [CsA]:  
At present CsA is the primary immunosuppressive agent 
used in solid organ transplantation.  
The drug inhibits the transcription of interleukin-2m RND, 
leading to decrease production of interlukin-2 and other cytokines 
critical to T-cells activation and proliferation. The major route of 
elimination is via biliary excretion.(6) Because of significant 
enterpatient and intrapatient variability in the extent of absorption 
after oral administration, as well as enterohepatic circulation, 
monitoring of CsA trough level should be employed as a gide to 
dosing changes. The usual oral starting dose is 8-15 mg/kg/day 
that is then tapered to a maintenance dose of 3-6 mg/kg/day 
approximately 6 months after transplantation.  
The intravenous dose of CsA is equivalent to one third of 
the oral dose.  
The most common complication seen with CsA is acute 
decline in renal function.(6)   
  16
In the earliest clinical renal transplant trials using CsA, a 
high incidence of oliguric A.T.N and primary nonfunction was 
observed; the risk was greatest with prolong ischaemia time of the 
donated kidney prior to transplantation.[23]  
Subsequent trials using lower doses of CsA showed that 
these problems were dose related, although there was considerable 
variability in the incidence of ATN in various centres.  
The histological changes associated with CsA 
nephrotoxicity are difficult to distinguish from chronic rejection. 
Other side effects associated with the use of CsA include 
hyperkalaemia, hypomagnaesaemia, gingival hypertrophy, 
tremors, seizures, hypertension and malignancies. Many drugs 
interactions that affect blood levels has been reported with CsA.(6)  
Tacrolimus:  
Amacrolide that block T-cells activation by mechanism 
very similar to that of CsA but with fewer rejection episodes.[3]  
Mycophenolate mofetil:  
Mycophenolate mofetil metabolized to mycophenolic acid 
and may supplant azathioprine an immunosuppression, as trial 
have shown a reduction in rejection episodes.(3)   
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Antilymphocytes and antithymocytes globulins:  
These are potent immunosuppressive agents. Antibodies 
may be polyclonal or monoclonal, derived from mouse, rabbis, 
horse or humanized and directed against any numbers of 
lymphocytes surface marker proteins enabling neutralization or 
killing of lymphocytes with certain function. Basiliximab is 
chimeric [human and mouse] CD25 monoclonal antibodies, which 
bind to IL-2 receptors inhibiting IL-2 driven proliferative 
responses.  
Recent trials have shown its safety, and when given 
prophylactically it reduces first time rejection by 40 percent.(3)    
Allograft dysfunction:  
A comprehensive evaluation is needed to eliminate, pre-
renal, parenchymal, post-renal and vascular aetiologies. However, 
immunological rejection and complications related to the surgical 
procedure are common problems that are unique to the transplant 
recipient.(6)  
Primary non-function:  
Is defined as lack of function immediately after 
engraftment, most of these grafts have sustained ischaemic injury 
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leading to ATN. Most will gain function in the 10-14 days after 
transplantation and are labeled as having delayed graft function. 
A minority of kidneys will never gain function and are 
thought to have primary allograft failure.(6)  
Pre-renal disease:  
Pre-renal azotaemia immediately after transplantation 
may occur if there an excessive fluid losses caused by diuresis. 
Primary cardiac disease, impaired vascular tone and other causes 
of intravascular volume depletion must also be considered.(6)  
Rejection:  
Immunologic rejection can be classified into four forms; 
hyper-acute, accelerated, acute and chronic based on temporal 
pathogenic and histologic distinctions.  
Hyperacute rejection:  
Mediated by transplant recipient preformed antibodies 
that recognize human leukocyte [H.L.A] antigen in the donor 
organ: Fibrinoid necrosis typically occurs within minutes to hours 
leading to almost immediate destruction of the allograft. 
Plasmapharesis may be beneficial in reversing the rejection process 
by eliminating the offending antibodies.(4)  
  19
Accelerated rejection:  
Generally occur in first 2 -4 days after transplantation. Can 
be mediated by either previously primed T-cells or humoral 
mechanism. The histological lesions are similar to those found in 
hyperacute rejection. Clinically this form of rejection presents as 
primary non-function or early initial function with rapid 
deterioration manifested as minimal urine output and graft 
demise.(6)  
Acute rejection:  
Mediated by activated T-cells that proliferates and attacks 
the allograft after recognizing antigens in the graft directly or after 
been processed by recipient antigen- presenting cells that present 
donor antigen to CD4 T-cells within the grooves of surface class II 
HLA molecules. It is usually recognized clinically by the 
development of unexplained ARF manifested by an acute rise in 
serum creatinine concentration and in severe case by oliguria. 
Episodes of acute rejection can occur at any time after 
transplantation. However, most cases occur within 6 months 
following transplantation. Traditionally, first line therapy of acute 
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rejection has consisted of high doses of corticosteroids 
administered either I.V or orally for 3-5 days.  
Resistant rejection is usually treated by antilymphocytic 
antibodies including OKT3 (monoclonal antibodies directed 
against the CD3 complex on the surface of activated T-cells). More 
than 90 percent of acute rejection episodes occurring in the first 6 
months after transplantation can be reversed. Treatment is less 
successful in patients with late acute rejection episodes [occurring 
more than one year after transplantation.(4)  
Chronic rejection:  
Manifested clinically by slow and gradual decline in renal 
allograft function. Usually beginning more than 6 months after 
transplantation and typically accompanied by moderate to heavy 
proteinuria.      
Histologically it is characterized by glomerulosclerosis, 
interstitial fibrosis and obliteration of arteriolar lumina. Because 
the pathophysiology of chronic rejection is poorly understood, 
treatment is unsatisfactory. Chronic rejection is currently the most 
common cause of long term renal allograft failure. A number of 
drugs including angiotensin converting enzyme inhibitors, 
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angiotensine receptor antagonist, and HMG coenzyme A reductase 
inhibitor prove to be effective in retarding the rate of progressive 
renal impairment in patient with chronic rejection.(4) 
Diagnosis of allograft dysfunction:  
When allograft dysfunction develops, a comprehensive 
evaluation is needed to eliminate pre-renal, parenchymal, post 
renal and vascular aetiologies. However, immunologic rejection 
and complication related to surgical procedure are common 
problems that are unique to transplant recipient.(6) 
The approach to the diagnosis of graft dysfunction 
includes a thorough history, including drug intake, and a physical 
examination. Laboratories data that should be obtained include a 
complete blood count, electrolytes, B.U.N, serum creatinine, CsA 
trough level, urinalysis and urine culture.  
In the setting of proteinuria, a 24 hours urine collection for 
protein should be obtained. In the absence of correctable pre-renal, 
post-renal and vascular cause, the next suggestive diagnostic test is 
kidney transplant biopsy. This may reveal A.T.N, rejection, CsA 
nephrotoxicity or recurrent of denovo-renal disease.(6)  
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Complications of renal transplantation:  
1- Technical problems:   
Haemorrhage; usually occur within 12 hours post-
operatively. Reduction in urine output and low central venous 
pressure which fail to respond promptly to colloid infusion should 
suggest this possibility. The diagnosis is rapidly confirmed by 
ultrasound showing a large perigraft haematoma. Early operation 
usually permits correction of the bleeding sources.(24)  
2- Vascular thrombosis:  
Vascular thrombosis may be arterial or venous. Arterial 
thrombosis usually occurs early, either immediately after 
transplantation or in the first few post-operative days. The 
diagnosis can be confirmed by ultrasound and isotopic scanning 
showing no pulsation and no perfusion. Venous thrombosis also 
occur early but is sometimes observed in the first few weeks after 
transplantation, even in grafts with previously good function. The 
presentation is often dramatic with loss of function, pain, and 
swelling of the graft.(24) 
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3- Infection:  
Chronic immunosuppression places the transplant 
recipients at risk for life threatening infections.  
The length of time post-transplantation, the amount of 
immunosuppression, and the level of renal function are helpful in 
determining the aetiology of infections. During the first 2-4 weeks 
after transplantation, infections are usually related to surgical 
procedure (generally bacterial) and those that were acquired 
before transplantation [e.g. H.B]. Reactivation of herpes simplex 
viruses with orolabial, oesophageal or genital involvement is also 
frequently seen.    
Beyond the first month post-transplantation opportunistic 
infections, with cytomegalovirus, mycobacterium, pneumonitis, 
listeria, aspergillus, nocardia, toxoplasma and cryptococcus 
become evident. This due to peak immunosuppressive effect of 
drug therapy.(6)  
Patients with central nervous system [C.N.S] infection 
often present with unexplained fever with headache, photophobia, 
or mental state changes. Because early clinical finding are often 
non-specific and because mortality rate may be as high as 50%, 
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cranial computerized tomography or magnetic resonance imagine 
scanning, lumbar puncture or both should not be delayed.(6) 
Urinary tract infection [U.T.I] is the most common 
infection encountered in renal transplant recipients, affecting 
approximately 30 to 40 percents of patients.[25] 
The major risk factors for U.T.I include indwelling 
catheters, handling and trauma to kidney and ureter during 
surgery, anatomic abnormalities of the native or transplanted 
kidneys, neurogenic bladder especially in diabetic patients and 
possibly rejection and immunosuppression.[26]  
The typical micro-organisms causing post transplant U.T.I 
are the enteric gram negative bacilli and enterococci. In addition, 
corynebacterium urealyticum has been recognized as a potential 
pathogen, which may be responsible for up to 10 percent of cases 
[versus less than 2 percent of U.T.Is in the general population}. 
This observation is clinically important because C-urealyticum is 
difficult to isolate and is not sensitive to conventional oral 
antibiotics. The antimicrobial of choice is vancomycin.[27]  
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4. Malignancies:  
The incidence of tumors in patients on 
immunosuppressive therapy is 5 to 6 percent or approximately 100 
times greater than that in general population of the same age 
range. The most common lesions are cancer of the skin and lips 
and carcinoma insitu of the cervix, as well as lymphomas, such as 
non-Hodgkin's lymphoma.  
   The risks are increased in proportion to the total 
immunosuppressive load administered and time elapsed since 
transplantation. Surveillance for skin and cervical cancer is 
necessary.(22)    
5- Cardiovascular system complications:  
Both chronic dialysis and renal transplantation have high 
incidence of death from myocardial infarction and stroke than in 
the general population and this particularly true in diabetic 
patients. Contributing factors are the use of glucocorticoids, 
hypertension and hypertriglyceridaemia. Increased low-density 
lipoprotein cholesterol concentration may be exaggerated after 
transplantation and require treatment. Recipients of renal 
transplant have a high prevalence of coronary artery and 
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peripheral vascular diseases. More than 50 percent of renal 
recipients' mortality is attributable to cardiovascular disease.(22)  
Hypertension, may be caused by native kidney, rejection, 
renal artery stenosis or renal calcineurin inhibitor toxicity. 
Whereas angiotensin converting enzyme [ACE] inhibitors may be 
useful, calcium channel blockers are more frequently used initially. 
Amelioration of hypertension to the 120-130/70-80 mm Hg range 
should be the goal in all patients.(22)    
6- Hypercalcaemia:  
Hypercalcaemia after transplantation may indicate failure 
of hyperplastic parathyroid gland to regress.  
Persistent hyperparathyroidism is common after renal 
transplantation.[28,29) As an example, approximately one-third of 
patients have persistent parathyroid hormone [PTH] 
hypersecretion post operatively if hypercalcaemia is used as a 
marker. The development of hypercalcaemia correlates with the 
duration of dialysis and parathyroid glands size,(30) and appears to 
be secondary to hyperplasia of the parathyroid glands rather than 
hypersecretion of individual cells.[31] The degree of parathyroid 
hyperplasia is so great in this setting that although the parathyroid 
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glands involute after transplantation, this process takes a few 
months [if mild] to several years to reach complications.[28,29]  
In addition to hyperparathyoidism, other factors can also 
contribute to an elevation in the plasma calcium concentration:  
• Resorption of soft tissue calcium phosphate deposits, which is 
often associated with persistent hyperphosphataemia.[28]    
• Normalization of calcitroid production, which both increase the 
PTH effect on bone and directly enhances intestinal calcium 
absorption.[32]  
•  To lesser degree, a rise in plasma albumin concentration [due 
to better nutrition.[29[  
7- Chronic hepatitis:  
Chronic hepatitis particularly when due to hepatitis B 
virus, can be aggressive, vetal disease over decade or so. Patients 
who are persistently HBs-Ag +ve are at high risk, according to 
some studies but the presence of H.C.V is also a concern when one 
embarks on a course of immunosuppression in transplant 
recipient.(22)  
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8- Recurrence of the primary renal disease after transplantation:  
The following diseases are known to recur after successful 
transplantation:  
a- Membranous nephropathy [MN]: Recurrence of MN in 
transplant is frequent with most studies reporting rate between 
three and seven percent.[33] 
b- Membranoproliferative glomerulonephritis: Both type I 
and type II membranoproliferative glomerulonephritis 
commonly recur after renal transplantation.(34)   
c- 1gA nephropathy:  it recurs in approximately 30 percent of cases 
after transplantation some patients have only histological 
recurrence, while other present with microscopic haematuria 
and a symptomatic proteinuria.(35) 
d- Focal glomerulosclerosis:  The exact rate at which primary focal 
glomerulosclerosis (FGS) recurs in the transplant is somewhat 
difficult to ascertain, because of the focal nature of the 
glomerular lesions can lead to sampling error in graft biopsies. 
The reported recurrence rate averages about 20 percent.(36)   
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OBJECTIVES  
 
The main objectives of the study are:  
1- To determine the percentage of normal renal graft function 5 
years after transplantation in patients attending Dr. Salma 
Mohamed Suleiman Centre for Dialysis and Kidney 
Transplantation  
2- To correlate between the duration of dialysis before renal 
transplantation and the percentage of the graft survival. 
3-  To correlate between the graft survival and gender of the 
donors. 
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PATIENTS AND METHODS  
Study design:  
This is retrospective study conducted in the period 
between January 2004 and June 2004 in Dr. Salma Mohamed 
Suleiman Centre for Dialysis and Kidney Transplantation The data 
was collected from files in the Statistic Department and the missed 
informations were taken directly from patients in the referred 
clinic and in Haemodialysis Ward for patients who returned to 
dialysis.  
Study population: 
Hundred cases of renal allograft recipients attending        
Dr. Salma Mohamed Suleiman Kidney Dialysis and 
Transplantation Centre, were taken randomly. The selection 
criterion was renal allograft recipients of 5 years duration or more. 
Data was then collected in questionnaire and according to last 
results of blood urea and serum creatinine, patients were 
categorized into patients with normal or impaired graft function. 
Those with impaired graft function subdivided, further into:  
• Patients with impaired graft function on conservative 
management.  
  31
• Patients with impaired graft function back to dialysis.   
• Patients with impaired renal function who had been lost 
from followup.  
Data analysis:  
The data was analyzed using statistical package for social 
science software (SPSS) computer, simple statistics frequency. 
Distribution and cross tabulation were done to determine the 
pattern of variables. Results were tested for statistical significance 
using student T-test, chi-square test where appropriate. A 
probability value of <0.05 was considered as statistically 
significant result, testing variation at 95 percent confidence or 
more.   
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RESULTS  
 
Fig. 1 demonstrates the sex distribution of renal allograft 
recipients. It shows that 63% of recipients were males and 27% 
were females.  
Fig. 2 demonstrates the sex distribution of the donors. It 
shows that 79% of donors were males and only 21% are females. 
Fig. 3 demonstrates the age distribution of renal allograft 
recipients. It shows that most of the recipients were in the age 
group of 41-50 years.  
Fig. 4 demonstrates the renal allograft function in study 
group. It shows that two third of recipients had normal renal graft  
function and one third had an impaired graft function.  
Fig. 5 demonstrates the outcome of patients with graft 
dysfunction, while 37.5% had graft dysfunction and still in 
conservative management, 31.22% return back to dialysis and 
31.4% had been lost from follow-up. 
Fig. 6 shows that 98% of patients received dialysis before 
transplantation and only in 2% preemptive transplantation was 
done.   
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Fig. 7 demonstrates the percentage of renal graft survival 
11-15 years after transplantation. It shows that 60% of recipients 
had normal graft function compared with 40% of those with 
impaired graft function.  
Table 1 demonstrates the type of dialysis before 
transplantation. It shows that 61% of patients received both haemo 
and peritoneal dialysis, 34% received HD only and 3% received 
P.D only.  
Table 2 demonstrates the relationship between age of the 
graft and graft survival. It shows that 70.3% of those with 
transplants done 5-10 years ago had normal graft function 
compared to 60% for those with transplant done 11-15 years ago. 
Only one percent (one patient) had his transplant done 25 years 
ago and had normal graft function.  
Table 3 demonstrates the relationship between renal graft 
survival and gender of the donor. It shows that 66.7% of those who 
were recipients of females kidneys had normal graft function 
compared with 68.6% of those who were recipients of male 
kidneys (Chi2 = 0.8).  
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Table 4 Demonstrates relationship between renal graft 
function and duration of dialysis before transplantation. It shows 
that the percentage of normal graft function is 100% in patients 
with pre-emptive transplantation compared to 21.4% in patients 
who underwent dialysis for more than 3 years before 
transplantation (Chi2 = 0,0005 highly significant).  
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Table 1: Dialysis before transplantation 
Haemodialysis   
Peritoneal dialysis  Yes  No 
Total 
Yes  
No 
61 
34 
3 
2 
64 
36 
Total  95 5 100 
 
 
Table 2: Relationship between age of the graft and graft survival 
Age group 
(in years)  
Patients with normal 
graft function 
Patients with impaired 
graft function 
Total 
5 - 10  52   (70.3%) 22   (29.7%) 74 
11 - 15  15  (60%)  10 (40%)  25 
> 16  1 (100%)  0 1 (100%) 
Total  68 (68%)  32 (32%)  100 (100%)  
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Table 3: Relationship between renal graft survival and gender of 
the donor  
Gender     
Male Female  
Total 
Patients with normal renal 
graft function  
54 (68.6%)  14 (66.7%)  68 
Patients with abnormal 
graft function  
25 (31.6%)  7 (33.3%)  32 
Total  79 21 100 
P = 0.883.  
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Table 4: Relationship between renal graft function and duration 
of dialysis before transplantation 
Duration  of 
dialysis  
Patients with abnormal 
graft function 
Patients with normal 
graft function 
Total 
0  0 (0.0%)  2(100%) 2 
< 6 months  7 (12.5%) 49 (87.5%) 56 
6 month - 1year 4 (40.0%) 6 (60%)  10 
1 - 3 years 10 (55.6%)  8 (44.4%)  18 
> 3 years  11 (78.6%) 3 (21.4%)  14 
Total  32 68   100 
   
P = 0.0005 (highly significant) 
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DISCUSSION  
 
Most of renal allograft recipients (63%) were males, this 
does not reflect that renal failure is commoner in males than 
females, but probably families seek medical care for male members 
because support of families depends on them.  
Only 21% of donors were females and this reflect our local 
customs that the males usually donate blood and organs, however, 
donation from mother to child and from sisters is becoming 
increasingly available.  
Most of the recipients were in the age group of 41-50 
because of lack of transplantation facilities and high cost of 
transplantation in the abroad.  
Of those who had impaired renal function, 31.22% (10 
patients) had been lost to follow-up and this most probably reflects 
mortality from graft loss, other causes, or travelling for re-
transplantation. So the exact number of mortality is difficult to   
estimated.   
Most of the patients (61%) received both haemo and 
peritoneal dialysis, which reflects lack of haemodialysis centers, so 
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most of the patients received peritoneal dialysis as an emergency 
for long time before finding a chance for haemodialysis and 
transplantation.  
According to the international data, the predicted half-life 
of allograft transplantation is 12.1 years (means that 12.1 years 
after transplantation, 50% of recipients had normal graft function). 
In this study 60% of those who received their transplantation 11-15 
years of age had normal graft function. This did not reflect that 
predicted half-life here is better because the centre receives 
recipients who passed the acute problems of transplantation in 
their transplant centres and the early mortality and morbidity is 
not included here.  
The study shows no difference in graft survival between 
recipients of males and female kidneys (68.6% versus 66.7%), this 
is against international data in which recipients of females kidneys 
had their predicted half-life reduced by 1.5 years compared with 
recipients of male kidneys. The discrepancy may reflect both low 
sample size and fewer number of female donors (21 female  donors 
only).  
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The study shows direct relation between duration of 
dialysis and graft dysfunction. The percentage of normal graft 
function in those with pre-emptive transplantation 100% 
compared with 21.4% of those who received dialysis for more than 
3 years before transplantation, this result is correlated well with 
available international data in which long duration of dialysis 
before transplantation is associated with greater risk of allograft 
failure.      
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CONCLUSION  
 
• Sixty three percent of graft recipients were males, whereas only 
21% of graft donors were females.  
• Most of allograft recipient (35%) were in age group between 
41-50 years and only 2% were of age >60 years.  
• Sixty eight percent of study group had normal allograft 
function five years or more after transplantation.  
• Most of the graft recipient (61%) received both peritoneal and 
haemo-dialysis before transplantation.  
• Ninety nine percent of study group had their graft age lie 
between 5-15 years.  
• No difference in allograft survival between recipients of male 
and female kidney in study group. 
• There is a direct relation between duration of dialysis before 
transplantation and allograft dysfunction.   
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RECOMMENDATIONS  
 
• Because of lack of facilities for dialysis and its high cost, renal 
transplantation should be the treatment of choice for patients 
with end stage renal disease in Sudan.  
• Most of patients with end stage renal disease can not afford cost 
of renal transplantation, so full financial support from the 
government or other organizations is required.  
• Training of renal transplant team is essential for successful 
renal transplant program.  
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Questionnaire 
Evaluation of allograft renal function in Dr. Salma Mohamed 
Suleiman Kidney Dialysis and Transplantation Centre 
 
- File No:.............................................                          - Serial No.: 
...............   
- Sex: ........................................          – Age:........................................ 
- Residence: ..............................................    - 
Occupation:............................  
- Marital status:............................ - Patient's weight:........................... kg. 
• Socioeconomic status:  ii- Low:         - Moderate         - High 
• Duration of renal failure before transplantation: 
i- < 6 months          ii- 6 - 12 months.        iii- 1 - 3 yrs         iv- > 3 yrs    
• Does the patient dialyzed before transplantation:  - Yes             - No   
• If "Yes" what type of dialysis used:   i- Haemodialysis:           ii- Peritoneal dialysis  
•  Duration of dialysis: ....................................................... 
• Does the patient had other medical problem:  - Yes             - No   
• If "Yes" specify:  
- D.M             - Hypertension          - Asthma          - Heart disease               
- Others ................................................................................................... 
            ................................................................................................... 
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             ................................................................................................... 
• Is the cause of renal failure known:                 - Yes             - No   
• If "Yes" specify: ............................................................................... 
• Date of renal transplantation: 
.................................................................... 
• Gender of the donor:      - Male            - Female 
• Age of the donor: ............................................................................... 
 
 
• Does the patient develop any complications after transplantation?  
                                                                                - Yes           - No   
• If "Yes" specify: ............................................................................... 
• Does the patient come for follow up regularly?  - Yes          - No   
• If "No" Why: ............................................................................... 
• Does the patient take his/her immuno-suppressants drugs daily?   
                                                                                - Yes          - No   
• If "No" Why: ............................................................................... 
• Last renal profile:  
- Serum creatinine: ..........................      - BUN: .........................                
 - Blood urea: ..................................       - S. Na+:........................      
 - S. K+: ..........................................        - S. Ca+2: ......................... 
- PSO4: ...................................... 
• If the patient has impaired renal function:  
              a- Is the cause known?                             - Yes                  - No 
• If "Yes" what is it? 
........................................................................................ 
b- What is the patient condition now?     
i- On conservative treatment             - Return to dialysis 
iii- Others (specify): .......................................................................                       
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